Heart Failure Reviews最新文献

Conduction system pacing in heart failure: Time for a paradigm shift? 心力衰竭的传导系统起搏：范式转变的时机已到？

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-11-23 DOI: 10.1007/s10741-024-10469-9

Panayotis K Vlachakis, Panagiotis Theofilis, Anastasios Apostolos, Athanasios Kordalis, Skevos Sideris, Georgios Leventopoulos, Stavros E Mountantonakis, Georgios Kollias, Ioannis Leontsinis, Maria Drakopoulou, Paschalis Karakasis, Dimitrios Tousoulis, Konstantinos Toutouzas, Dimitrios Tsiachris, Konstantinos Gatzoulis, Costas Tsioufis

{"title":"Conduction system pacing in heart failure: Time for a paradigm shift?","authors":"Panayotis K Vlachakis, Panagiotis Theofilis, Anastasios Apostolos, Athanasios Kordalis, Skevos Sideris, Georgios Leventopoulos, Stavros E Mountantonakis, Georgios Kollias, Ioannis Leontsinis, Maria Drakopoulou, Paschalis Karakasis, Dimitrios Tousoulis, Konstantinos Toutouzas, Dimitrios Tsiachris, Konstantinos Gatzoulis, Costas Tsioufis","doi":"10.1007/s10741-024-10469-9","DOIUrl":"https://doi.org/10.1007/s10741-024-10469-9","url":null,"abstract":"Heart failure (HF) is a major clinical challenge characterized by significant morbidity and mortality. Electrical conduction abnormalities play a critical role in HF pathophysiology and progression, often leading to suboptimal outcomes with conventional pacing techniques. Con-duction system pacing (CSP), encompassing His bundle pacing and left bundle branch area pacing, has emerged as a novel approach. Despite data come from observational studies, recent guidelines recommend that a specific population may benefit from CSP. However, significant practical considerations and challenges need to be clarified before CSP can be routinely implemented in clinical practice. The reliance on observational studies means that long-term clinical outcomes for HF patients remain uncertain until data from randomized controlled trials (RCTs) become available. Current CSP practices face challenges with lead implantation, mechanical stress on leads, and the need for more advanced tools and artificial intelligence integration to improve procedure efficacy and safety. Future large-scale RCTs are essential to identify optimal candidates and address these technical challenges, potentially leading to a paradigm shift in HF management.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could SGLT2 inhibitors improve outcomes in patients with heart failure and significant valvular heart disease? Need for action. SGLT2 抑制剂能否改善心力衰竭合并严重瓣膜性心脏病患者的预后？需要采取行动。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-11-20 DOI: 10.1007/s10741-024-10467-x

Vasileios Kamperidis, Vasileios Anastasiou, Antonios Ziakas

引用次数: 0

Maternal heart failure: state-of-the-art review. 产妇心力衰竭：最新综述。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-11-12 DOI: 10.1007/s10741-024-10466-y

Usman S Najam, Jitae A Kim, Sophie Y Kim, Gurleen Wander, Mario Rodriguez, Hafeez Ul Hassan Virk, Mark R Johnson, W H Wilson Tang, Chayakrit Krittanawong

{"title":"Maternal heart failure: state-of-the-art review.","authors":"Usman S Najam, Jitae A Kim, Sophie Y Kim, Gurleen Wander, Mario Rodriguez, Hafeez Ul Hassan Virk, Mark R Johnson, W H Wilson Tang, Chayakrit Krittanawong","doi":"10.1007/s10741-024-10466-y","DOIUrl":"https://doi.org/10.1007/s10741-024-10466-y","url":null,"abstract":"Pregnancy is a period of substantial changes to the body's normal physiology, and the failure to adapt to these changes can lead to life-threatening pathology, particularly involving the cardiovascular system. In comparison to pre-pregnancy physiology, pregnant women have increased blood volume and physical demands which exert increased stress on the heart. This is important to consider in women with and without previously diagnosed cardiovascular disease, as the physiologic changes during pregnancy and postpartum can lead to sudden decompensation. The management of heart failure is particularly important as it remains the most common cardiovascular complication during pregnancy and is associated with substantial maternal and fetal morbidity and mortality. This is especially true in patients with pre-existing heart failure, who should receive counseling before conception and in certain cases be advised against pregnancy. For these reasons, healthcare professionals must be well-versed in the different strategies of diagnosis, management, treatment, and monitoring. This review will outline the pathophysiology, diagnostics, management, and general approach to heart failure in pregnant patients.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines. 肥厚型心肌病的诊断和管理：欧洲与美国的指南。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-11-09 DOI: 10.1007/s10741-024-10464-0

Alberto Aimo, Giancarlo Todiere, Andrea Barison, Daniela Tomasoni, Giorgia Panichella, Ahmad Masri, Martin S Maron

{"title":"Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines.","authors":"Alberto Aimo, Giancarlo Todiere, Andrea Barison, Daniela Tomasoni, Giorgia Panichella, Ahmad Masri, Martin S Maron","doi":"10.1007/s10741-024-10464-0","DOIUrl":"https://doi.org/10.1007/s10741-024-10464-0","url":null,"abstract":"Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, affecting 1:200 to 1:500 individuals worldwide. Guidelines on the diagnosis and management of HCM have been recently published by the European Society of Cardiology (ESC) and American societies. The ESC guidelines cover a broad range of cardiomyopathies, including HCM, with 119 recommendations, whereas the American guidelines focus exclusively on HCM with 141 specific recommendations. Both guidelines emphasize a comprehensive diagnostic approach, including imaging and genetic testing, but differ in some specific aspects. For example, sudden cardiac death (SCD) risk assessment is a primary point of divergence. The ESC guidelines advocate for the use of a validated Risk-SCD calculator, while the American guidelines rely on specific risk markers for individualized risk evaluation. Management strategies also vary: both guidelines prioritize beta-blockers and calcium channel blockers in patients with resting or provocable left ventricular outflow tract (LVOT) obstruction. If beta-blockers (or verapamil/diltiazem) are ineffective, either disopyramide or the myosin inhibitor mavacamten may be an option with slightly different indications among the two guidelines. Septal reduction therapy is recommended in ESC guidelines for symptomatic patients with significant LVOT gradients, while American guidelines suggest earlier myectomy for certain clinical factors and emphasize shared decision-making. The ESC guidelines recommend sequential atrioventricular pacing and dual-chamber defibrillators for reducing LVOT gradients. The American guidelines focus on genetic testing for risk assessment and suggest periodic cardiac magnetic resonance imaging. This paper provides a detailed comparison of these guidelines, highlighting key differences and areas needing further research and expert debate.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sodium-glucose co-transporter 2 inhibitors in left ventricular assist device and heart transplant recipients: a mini-review. 左心室辅助装置和心脏移植受者体内的钠-葡萄糖协同转运体 2 抑制剂：微型综述。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-11-08 DOI: 10.1007/s10741-024-10465-z

Emyal Alyaydin, Danaë Parianos, Julia Hermes-Laufer, Matthias P Nägele, Liesa Castro, Maria Papathanasiou, Holger Reinecke, Andreas J Flammer

{"title":"Sodium-glucose co-transporter 2 inhibitors in left ventricular assist device and heart transplant recipients: a mini-review.","authors":"Emyal Alyaydin, Danaë Parianos, Julia Hermes-Laufer, Matthias P Nägele, Liesa Castro, Maria Papathanasiou, Holger Reinecke, Andreas J Flammer","doi":"10.1007/s10741-024-10465-z","DOIUrl":"https://doi.org/10.1007/s10741-024-10465-z","url":null,"abstract":"In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) emerged as promising therapeutic agents in managing heart failure (HF). They demonstrated a significant impact on reducing HF hospitalizations and related mortality in patients with reduced and preserved ejection fraction. However, evidence supporting their use in patients with left ventricular assist device (LVAD) and heart transplant (HT) recipients is still limited. We identified six key studies investigating the safety and efficacy of SGLT2i in LVAD and HT recipients. In patients with LVAD, prescription of SGLT2i was predominantly associated with improved fluid management and reduced pulmonary artery pressures. However, the results regarding their effects on body weight, hemoglobin A1c, diuretic use, and right ventricular function were contradictory. In terms of safety, SGLT2i were generally well-tolerated in the LVAD population, and the reported incidence of adverse events was low. In HT recipients, SGLT2i were associated with better glycemic control and weight reduction. No relevant adverse events were reported. Despite these encouraging results, the long-term safety and efficacy of SGLT2i in these vulnerable patient populations are yet to be investigated. Future randomized controlled trials are needed to address existing gaps in evidence and help integrate SGLT2i into clinical practice for LVAD and HT recipients.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The road to renal denervation for hypertension and beyond (HF): two decades of failed, succeeded, and to be determined. 高血压及其他疾病（HF）的肾脏神经支配之路：二十年的失败、成功和待定。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-11-07 DOI: 10.1007/s10741-024-10463-1

Haoran Jiang, Veraprapas Kittipibul, Felix Mahfoud, Michael Böhm, Paul A Sobotka, Murray Esler, Jie Wang, Marat Fudim

引用次数: 0

Adrenal crisis-induced cardiogenic shock (ACCS): a comprehensive review. 肾上腺危象诱发的心源性休克（ACCS）：全面回顾。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-11-06 DOI: 10.1007/s10741-024-10458-y

Maryam Heidarpour, Davood Shafie, Reza Eshraghi, Seyed Reza Mirjalili, Ashkan Bahrami, Mohammad Reza Movahed

引用次数: 0

Digital health as a tool for patient activation and improving quality of care for heart failure. 将数字医疗作为激活患者和提高心力衰竭护理质量的工具。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-11-01 Epub Date: 2024-09-06 DOI: 10.1007/s10741-024-10433-7

Aradhana Verma, Zahra Azizi, Alexander T Sandhu

{"title":"Digital health as a tool for patient activation and improving quality of care for heart failure.","authors":"Aradhana Verma, Zahra Azizi, Alexander T Sandhu","doi":"10.1007/s10741-024-10433-7","DOIUrl":"10.1007/s10741-024-10433-7","url":null,"abstract":"The clinical and economic impact of heart failure (HF) is immense and will continue to rise due to the increasing prevalence of the disease. Despite the availability of guideline-recommended medications that improve mortality, reduce hospitalizations, and enhance quality of life, there are major gaps in the implementation of such care. Quality improvement interventions have generally focused on clinicians. While certain interventions have had modest success in improving the use of heart failure medications, they remain insufficient in optimizing HF care. Here, we discuss how patient-facing interventions can add value and supplement clinician-centered interventions. We discuss how digital health can be leveraged to create patient activation tools that create a larger, sustainable impact. Small studies have suggested the promise of digital tools for patient engagement and self-care, but there are also important barriers to the adoption of such interventions that we describe. We share key principles and strategies around the design and implementation of digital health innovations to maximize patient participation and engagement. By uniquely activating patients in their own care, digital health can unlock the full potential of both existing and new quality improvement initiatives to drive forward high-quality and equitable heart failure care.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1239-1245"},"PeriodicalIF":4.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence and myocarditis-a systematic review of current applications. 人工智能与心肌炎--当前应用的系统回顾。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-11-01 Epub Date: 2024-08-14 DOI: 10.1007/s10741-024-10431-9

Paweł Marek Łajczak, Kamil Jóźwik

{"title":"Artificial intelligence and myocarditis-a systematic review of current applications.","authors":"Paweł Marek Łajczak, Kamil Jóźwik","doi":"10.1007/s10741-024-10431-9","DOIUrl":"10.1007/s10741-024-10431-9","url":null,"abstract":"Myocarditis, marked by heart muscle inflammation, poses significant clinical challenges. This study, guided by PRISMA guidelines, explores the expanding role of artificial intelligence (AI) in myocarditis, aiming to consolidate current knowledge and guide future research. Following PRISMA guidelines, a systematic review was conducted across PubMed, Cochrane Reviews, Scopus, Embase, and Web of Science databases. MeSH terms including artificial intelligence, deep learning, machine learning, myocarditis, and inflammatory cardiomyopathy were used. Inclusion criteria involved original articles utilizing AI for myocarditis, while exclusion criteria eliminated reviews, editorials, and non-AI-focused studies. The search yielded 616 articles, with 42 meeting inclusion criteria after screening. The identified articles, spanning diagnostic, survival prediction, and molecular analysis aspects, were analyzed in each subsection. Diagnostic studies showcased the versatility of AI algorithms, achieving high accuracies in myocarditis detection. Survival prediction models exhibited robust discriminatory power, particularly in emergency settings and pediatric populations. Molecular analyses demonstrated AI's potential in deciphering complex immune interactions. This systematic review provides a comprehensive overview of AI applications in myocarditis, highlighting transformative potential in diagnostics, survival prediction, and molecular understanding. Collaborative efforts are crucial for overcoming limitations and realizing AI's full potential in improving myocarditis care.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1217-1234"},"PeriodicalIF":4.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11455665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Embracing an era of targeted combination therapy for heart failure with preserved ejection fraction. 迎接射血分数保留型心力衰竭靶向综合疗法时代的到来。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-11-01 Epub Date: 2024-08-27 DOI: 10.1007/s10741-024-10432-8

Satoshi Shoji, Stephen J Greene, Robert J Mentz

{"title":"Embracing an era of targeted combination therapy for heart failure with preserved ejection fraction.","authors":"Satoshi Shoji, Stephen J Greene, Robert J Mentz","doi":"10.1007/s10741-024-10432-8","DOIUrl":"10.1007/s10741-024-10432-8","url":null,"abstract":"The concept of quadruple therapy as a \"one-size-fit-all\" approach is effective among all eligible patients with heart failure with reduced ejection fraction, with consistent and significant clinical benefits including reduced mortality across various subgroups. However, with exception of sodium-glucose cotransporter 2 inhibitors, the consistency of benefit with therapies does not extend to patients with heart failure with preserved ejection fraction. The clinical benefits of other promising medical therapies, such as angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists, have been demonstrated only in certain phenotypes of the highly heterogenous heart failure with preserved ejection fraction population. This variability can confuse frontline practicing cardiologists, potentially leading to the under-implementation of these medications. Therefore, we propose a simple approach: \"targeted\" combination therapy. This strategy aims to optimize evidence-based medications in heart failure with preserved ejection fraction by tailoring treatments to specific subgroups within the heart failure with preserved ejection fraction population where significant benefits are most evident.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1235-1238"},"PeriodicalIF":4.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0